Curated news and analysis on clinical trials, drug approvals, and medical research.
Northeast Florida has moved into Phase III drought conditions, tightening irrigation and other non-essential water uses. Officials cited below-average rainfall, dropping groundwater levels and a rainfall deficit of more than 25 inches year over year.
Baxfendy was approved in the US for hypertension in adults not adequately controlled on other antihypertensive medicines. The approval was based on Phase III BaxHTN results showing significant systolic blood pressure reductions.
Wegovy and Mounjaro prices in South Korea are higher than in China and Japan. South Korea added both drugs to a non-insurance reporting system, but immediate price cuts are unlikely.
Charles River forecast 2026 adjusted EPS of $10.70 to $11.20, above the $10.88 consensus. The company cited improving biotech demand and said Q1 profit will decline in the high-teens.
A real-world analysis found BRAF V600E-mutated papillary thyroid cancer had a proinflammatory molecular profile, but no significant overall survival difference versus BRAF wild-type disease. Treatment choice among BRAF/MEK inhibitors, tyrosine kinase inhibitors, and immunotherapy was not associated with significant survival differences.
People with Down syndrome have a 90% to 95% lifetime risk of Alzheimer’s disease. Amyloid accumulation is almost inevitable by age 40, and baseline assessment is recommended by age 40 with annual follow-up.
Nurix reported new oncology preclinical data at AACR 2026 and outlined progress in its immunology degrader pipeline. The company said NX-3911 could enter an IND this year and Phase 1 data for bexobrutideg are planned this year.
Compass Pathways said COMP360 for treatment-resistant depression retains FDA Breakthrough Therapy designation as it advances in phase 3. A Trump executive order also directs faster federal review of psychedelic drugs with breakthrough status.
Ebola Virus Disease remains a public health concern due to its high fatality rate. A new outbreak has been confirmed in Congo’s Ituri province, while early treatment and approved monoclonal antibodies can enhance survival.
Studies linked better overall brain health, higher midlife vitamin D levels and lifelong intellectual activity with lower Alzheimer’s-related vulnerability. Findings included lower tau pathology, delayed mild cognitive impairment and dementia onset, and higher cognitive resilience.
United Therapeutics received FDA clearance under an Investigational New Drug application to begin a clinical trial of its pig-derived UHeart xenotransplant. The Phase 1/2/3 EXPRESS study starts with up to 2 participants.
A Neuron study reported that partial reprogramming of engram neurons with OSK restored memory in aged mice and improved learning and long-term memory in Alzheimer’s mouse models.
4D Molecular Therapeutics said 4D-150 is in Phase 3 for wet AMD and nearing Phase 3 in diabetic macular edema. The company reported rapid enrollment, 18-month treatment burden reductions and favorable safety data.
TuHURA Biosciences said the FDA granted orphan drug designation to IFx-2.0 for stage IIB to stage IV cutaneous melanoma based on Phase 1 data. The company said its Phase 3 IFx-2.0 study in first-line Merkel cell carcinoma continues to enroll.
ImmunityBio said the Saudi FDA encouraged submission of a regulatory package for recombinant BCG and opened talks on expanding ANKTIVA with checkpoint inhibitors to additional tumor types. The company expects to file the rBCG package within weeks.
Pfizer is running a Phase 1 open-label multiple-dose study of PF-08653944 in adults with overweight or obesity. The study will assess gastric emptying and safety, with an update filed on 20 April 2026.
A novel series of coumarin–cyanoacetohydrazide hybrids was synthesized and tested against phytopathogenic fungi. Compound 8 showed the broadest antifungal spectrum and highest inhibition potency.
Phase 2 Co-PSMA trial shows 64Cu-SAR-bisPSMA PET/CT detected 63 prostate cancer lesions vs 24 with 68Ga-PSMA-11, with 78% vs 36% positive scans. Results changed management in 44% of patients.
CRISPR Therapeutics said CASGEVY launch momentum is building and multiple pipeline assets could generate data in the next 12 to 18 months. The company also highlighted zugo-cel progress in oncology and autoimmune disease.
The FDA approved Tecentriq and Tecentriq Hybreza for adjuvant muscle-invasive bladder cancer with ctDNA molecular residual disease after cystectomy. The Phase III IMvigor011 study showed a 36% reduction in recurrence or death and a 41% reduction in death.
